US 12,458,652 B2
Pharmaceutical compositions of spironolactone for deep dermal drug delivery
David W. Osborne, Fort Collins, CO (US); and Babak N. Tofig, Westlake Village, CA (US)
Assigned to ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US)
Filed by ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US)
Filed on Nov. 10, 2022, as Appl. No. 17/984,405.
Claims priority of provisional application 63/278,377, filed on Nov. 11, 2021.
Prior Publication US 2023/0143609 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/585 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 9/12 (2006.01); A61K 47/20 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/585 (2013.01) [A61K 9/0014 (2013.01); A61K 9/009 (2013.01); A61K 9/107 (2013.01); A61K 9/122 (2013.01); A61K 47/20 (2013.01); A61K 47/38 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A topical pharmaceutical composition comprising:
a therapeutically effective amount of about 0.10% w/w to about 7.5% w/w of spironolactone or a pharmaceutically acceptable salt thereof, wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 0.25 μm; and
water,
wherein the spironolactone is suspended in water.